# Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

> **NCT00002855** · PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 306 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Bicalutamide
- **DRUG:** Doxorubicin hydrochloride
- **DRUG:** Estramustine Phosphate Sodium
- **DRUG:** Flutamide
- **DRUG:** Ketoconazole
- **DRUG:** Nilutamide
- **DRUG:** Therapeutic Hydrocortisone
- **DRUG:** Vinblastine
- **PROCEDURE:** Conventional Surgery

## Key facts

- **NCT ID:** NCT00002855
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-08
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002855, "Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00002855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*